Bloom MD review

Bloom MD’s current product pages show one-time and discounted subscription offers for sermorelin and NAD⁺. Those billing intervals do not establish prescribed supply duration or the complete charge. Its homepage directs prescription patients to Bask, with a legacy MDI portal until transfer. Current product-specific pharmacy assignment and three different cancellation deadlines still need written confirmation.

Bloom MD (styled BloomMD) is a direct-to-consumer telehealth storefront covering weight loss, longevity, hormones, skin and hair, with a Utah number you can text to reach a practitioner. Its longevity line includes sermorelin, NAD⁺ as an injection or nasal spray, and glutathione as an injection or nasal spray, alongside low-dose naltrexone, methylene blue and MIC-B12. The September 2026 catalog also described compounded semaglutide on a flat any-dose plan, compounded tirzepatide priced up a published dose ladder, liraglutide, a tirzepatide microdose option, oral GLP-1 drops, and membership programs for brand-name Wegovy, Zepbound and the Wegovy and Foundayo pills. The current homepage routes prescription patients to Bask; existing MDI patients retain a legacy portal until transferred. Its May 2024 MDI terms describe a separation between administrative services and clinical care.

The homepage directs prescription patients to Bask and keeps a legacy MDI portal until transfer. The FAQ describes a health questionnaire, licensed-provider review and free consultation, with self-pay services and product/state/provider/pharmacy availability varying; no exact state list is given. Dated May 2024 terms identify HAWS CAPITAL LLC DBA BloomMD and name Strive Compounding Pharmacy, without confirming the current Bask care team. Those terms prohibit under-18 use, while legacy MDI terms allow a guardian exception; neither establishes current Bask age eligibility. Confirm labs, assigned clinician and pharmacy, shipping charges and eligibility.

The sermorelin page offers $195 one-time or $185.25 for a monthly subscription. Earlier 3 mL/1000 mcg-per-mL specifications and supplies remain in auxiliary product text, without a current visible supply-duration commitment. NAD⁺ injection options show 1200 mg/6 mL at $245 one-time or $232.75 monthly, and 2000 mg/10 mL at $395 one-time or $375.25 monthly or every six weeks. Subscriptions renew at the selected interval; this does not establish how long a prescribed vial lasts or what shipping, taxes and other fees add.

Product text says cancel before renewal and that cancellation does not undo placed orders. The refund policy requires seven days’ notice; dated terms require two weeks and restrict refunds after payment. Dispensed prescriptions cannot be returned, and damaged or incorrect orders must be reported within seven days. Older thirty-day money-back and free-delivery wording is absent from the visible offer and does not override those refund restrictions. Obtain the terms for your selected plan.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The peptide products and the compounded GLP-1s are compounding-pharmacy preparations, not therapeutically equivalent to branded drugs, and dated May 15, 2024 terms name Strive Compounding Pharmacy without confirming current product-specific fulfillment; the brand-name Wegovy, Zepbound and Foundayo options are FDA-approved and a separate tier. On the evidence, the wellness line splits cleanly into three. Sermorelin acts on the growth-hormone axis, a real and well-described mechanism with thin long-term human outcome data and no controlled trial behind the recovery or body-composition claims made for it. Injected or intranasal NAD⁺ has no controlled human outcome trials; the oral precursors NR and NMN are the forms with human data, and what they establish is a raised blood NAD⁺ level rather than a clinical benefit. Glutathione, injected or intranasal, has essentially no controlled human outcome evidence for the wellness and skin claims attached to it. One more note that belongs here: the microdose GLP-1 option on the same catalog uses sub-therapeutic dosing, which has a thinner trial base than full-dose therapy and should be expected to do less. Individual results vary.